
## Masataka Suzuki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9137587/publications.pdf Version: 2024-02-01



MASATAKA SUZUKI

#	Article	IF	CITATIONS
1	HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy. Cancers, 2022, 14, 2769.	3.7	8
2	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Molecular Therapy, 2021, 29, 505-520.	8.2	48
3	Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells. Advances in Cell and Gene Therapy, 2021, 4, e99.	0.9	10
4	Three Decades of Clinical Gene Therapy: From Experimental Technologies to Viable Treatments. Molecular Therapy, 2021, 29, 411-412.	8.2	4
5	Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigenâ€specific immunotherapy. Head and Neck, 2021, 43, 1983-1994.	2.0	4
6	Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Communications Biology, 2021, 4, 368.	4.4	23
7	Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Molecular Therapy, 2021, 29, 1808-1820.	8.2	34
8	Current development in adenoviral vectors for cancer immunotherapy. Molecular Therapy - Oncolytics, 2021, 23, 571-581.	4.4	7
9	Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Molecular Therapy, 2020, 28, 1251-1262.	8.2	89
10	Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives. Cancers, 2020, 12, 619.	3.7	11
11	Immunology of Adenoviral Vectors in Cancer Therapy. Molecular Therapy - Methods and Clinical Development, 2019, 15, 418-429.	4.1	54
12	Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment. Frontiers in Immunology, 2018, 9, 2103.	4.8	56
13	Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Research, 2017, 77, 2040-2051.	0.9	170
14	Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies. Molecular Therapy, 2017, 25, 836-838.	8.2	4
15	Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Molecular Therapy, 2017, 25, 2440-2451.	8.2	151
16	Recent advances in oncolytic adenovirus therapies for cancer. Current Opinion in Virology, 2016, 21, 9-15.	5.4	77
17	Restoration of the serum level of SERPINF1 does not correct the bone phenotype in Serpinf1 null mice. Molecular Genetics and Metabolism, 2016, 117, 378-382.	1.1	12
18	Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Molecular Therapy, 2015, 23, 1497-1506.	8.2	28

MASATAKA SUZUKI

#	Article	IF	CITATIONS
19	Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy. Biomedicines, 2014, 2, 110-131.	3.2	3
20	Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Molecular Therapy - Oncolytics, 2014, 1, 14008.	4.4	19
21	Differential Type I Interferon-dependent Transgene Silencing of Helper-dependent Adenoviral vs. Adeno-associated Viral Vectors In Vivo. Molecular Therapy, 2013, 21, 796-805.	8.2	40
22	Capsid-Modified Adenoviral Vectors for Improved Muscle-Directed Gene Therapy. Human Gene Therapy, 2012, 23, 1065-1070.	2.7	25
23	Adenovirus Immunity: X Marks the Spot. Molecular Therapy, 2012, 20, 2197-2198.	8.2	3
24	NOD2 Signaling Contributes to the Innate Immune Response Against Helper-Dependent Adenovirus Vectors Independently of MyD88 <i>In Vivo</i> . Human Gene Therapy, 2011, 22, 1071-1082.	2.7	22
25	MyD88-Dependent Silencing of Transgene Expression During the Innate and Adaptive Immune Response to Helper-Dependent Adenovirus. Human Gene Therapy, 2010, 21, 325-336.	2.7	31
26	Large-Scale Production of High-Quality Helper-Dependent Adenoviral Vectors Using Adherent Cells in Cell Factories. Human Gene Therapy, 2010, 21, 120-126.	2.7	35
27	Self-Complementary AAV Vectors Cause a Substantially Heightened TLR9-Dependent Innate Immune Response In the Liver. Blood, 2010, 116, 252-252.	1.4	1
28	Early STAT1 Activation After Systemic Delivery of HSV Amplicon Vectors Suppresses Transcription of The Vector-encoded Transgene. Molecular Therapy, 2007, 15, 2017-2026.	8.2	27